Ms. Wendell was appointed to our Board in December 2016. From January 2016 to May 2019, Ms. Wendell was a Senior Advisor for Perella Weinberg Partner's Healthcare Investment Banking Practice, providing guidance and advice with respect to mergers and acquisitions and divestitures for clients and assisting the firm in connection with firm-level transactions. From 2015 to September 2018, Ms. Wendell served as a Senior Advisor for McKinsey's Strategy and Corporate Finance Practice and also served as a member of McKinsey's Transactions Advisory Board to help define trends in mergers and acquisitions, as well as help shape McKinsey's knowledge agenda. From 1986 until January 2015, Ms. Wendell held various roles of increasing responsibility at Covidien plc (including its predecessors, Tyco Healthcare and Kendall Healthcare Products), including engineering, product management and business development. Most recently, from December 2006 until Covidien's acquisition by Medtronic plc in January 2015, she served as Senior Vice President of Strategy and Business Development, where she led the company's strategy and portfolio management initiatives and managed all business development, including acquisitions, equity investments, divestitures and licensing/distribution. Ms. Wendell also serves on the boards of AxoGen, Inc., where she is a member of the Audit Committee and the Compensation Committee; Solventum Corp., where she is a member of the Governance Committee and the Science, Technology and Quality Committee; and at Baxter International, Inc., where she is a member of the Quality, Compliance and Technology Committee. She is Chairman of the Board of Por Cristo, a non-profit charitable medical service organization involved in healthcare work for at-risk women and children in Latin America. Ms. Wendell holds a Bachelor of Science in mechanical engineering from Lawrence Technological University and a Master of Science degree in biomedical engineering from the University of Illinois.
Member of the Compensation Committee
Chair of the Nominating and Corporate Governance Committee